Vigabatrin is an antiepileptic drug that produces intramyelinic edema in several animal models. This study investigates the effect of vigabatrin on the developing human brain. The authors retrospectively blindly review 34 brain magnetic resonance imaging of 22 epileptic infants (age: 9 ± 1 months) that received vigabatrin, focusing on the presence of hyperintensity on T2- and diffusion-weighted images. Patients treated with vigabatrin displayed significant magnetic resonance imaging hyperintensity of basal ganglia and brain stem (P < .001, Wilcoxon test). This hyperintensity was transient and maximal 3 to 6 months after the beginning of vigabatrin. Hyperintensity was independent from duration and type of epilepsy, and from the presence or absence of seizures. The authors conclude that vigabatrin treatment is associated with transient hypersignal of the basal ganglia and brain stem in epileptic infants. Such transient hyperintensity is likely to be age-dependent and time-dependent because it has never been observed in adult patients.
Schechter PJClinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27:S19-S22.
2.
Sander JW, Trevisol-Bittencourt PC, Hart YM, Shorvon SDEvaluation of vigabatrin as an add-on drug in the management of severe epilepsy . J Neurol Neurosurg Psychiatry. 1990;53: 1008-1010.
3.
French JA, Mosier M., Walker S., Sommerville K., Sussman N.A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology. 1996;46:54-61.
4.
Wild JM, Ahn HS, Baulac M., et al. Vigabatrin and epilepsy: lessons learned. Epilepsia . 2007;48:1318-1327.
5.
Chiron C., Dulac O., Luna D., et al. Vigabatrin in infantile spasms. Lancet. 1990;335:363-364.
6.
Aicardi J., Mumford JP, Dumas C., Wood S.Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia . 1996;37:638-642.
7.
Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O.Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997 ; 26:389-395.
8.
Vigevano F., Cilio MRVigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 1997;38:1270-1274.
9.
Wohlrab G., Boltshauser E., Schmitt B.Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics. 1998;29:133-136.
10.
Villeneuve N., Soufflet C., Plouin P., Chiron C., Dulac O.Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants. Arch Pediatr. 1998;5:731-738.
11.
Granstrom ML , Gaily E., Liukkonen E.Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia. 1999;40:950-957.
12.
Appleton RE , Peters AC, Mumford JP, Shaw DERandomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 1999;40:1627-1633.
13.
Cossette P. , Riviello JJ, Carmant L.ACTH versus vigabatrin therapy in infantile spasms: a retrospective study. Neurology. 1999;52:1691-1694.
14.
Elterman RD , Shields WD, Mansfield KA, Nakagawa J., and the US Infantile Spasms Vigabatrin Study Group.Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416-1421.
15.
Hancock E., Osborne JP, Milner P.The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev. 2001;23:624-634.
16.
Mikati MA, Lepejian GA, Holmes GLMedical treatment of patients with infantile spasms. Clin Neuropharmacol. 2002; 25:61-70.
17.
Mackay MT, Weiss SK, Adams-Webber T., et al. American Academy of Neurology; Child Neurology Society. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;25;62:1668-81.
18.
Grunewald RA, Thompson PJ, Corcoran R., Corden Z., Jackson GD, Duncan JSEffects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry. 1994;57:1057-1063.
19.
Nabbout RC, Chiron C., Mumford J., Dumas C., Dulac O.Vigabatrin in partial seizures in children. J Child Neurol . 1997;12:172-177.
20.
Coppola G., Terraciano AM, Pascotto A.Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. Brain Dev. 1997;19:459-463.
21.
Bruni J., Guberman A., Vachon L., Desforges C.Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group . Seizure. 2000;9:224-232.
22.
Butler WH, Ford GP, Newberne JWA study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15143-15148.
23.
Butler WHThe neuropathology of vigabatrin. Epilepsia. 1989;30:S15-S17.
24.
Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JWChronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 1990;18:225-238.
25.
Yarrington JT, Gibson JP, Dillberger JE, et al. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 1993;21:480-489.
26.
Jackson GD, Williams SR, Weller RO, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 1994;18:57-66.
27.
Weiss KL, Schroeder CE, Kastin SJ, et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 1994;44:1944-1949.
28.
Peyster RG, Sussman NM, Hershey BL, et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia . 1995; 36:93-100.
29.
Qiao M., Malisza KL, Del Bigio MR, Kozlowski P., Seshia SS, Tuor UIEffect of long-term vigabatrin administration on the immature rat brain. Epilepsia. 2000;41:655-665.
30.
Preece NE, Houseman J., King MD, Weller RO, Williams SRDevelopment of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse . 2004;53:36-43.
31.
Cocito L., Maffini M., Loeb C.MRI findings in epileptic patients on vigabatrin for more than 5 years. Seizure. 1992;1: 163-165.
32.
Van Paesschen W., Duncan JS, Connelly A.A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements. Epilepsy Res. 1998;29:155-160.
33.
Cannon DJ, Butler WH, Mumford JP, Lewis PJNeuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol. 1991;(suppl 2): S17-S24.
34.
Pearl PL, Molloy-Wells E., McClintock WM, et al. MRI abnormalities associated with vigabatrin therapy: higher risk in infants? (abstract). Epilepsia. 2006 ;47:S14.
35.
Proposal for revised classification of epilepsies and epileptic syndrome.Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30: 389-399.
36.
Desguerre I. , Marti I., Valayannopoulos V., et al. Transient magnetic resonance diffusion abnormalities in West syndrome: the radiological expression of non-convulsive status epilepticus? Dev Med Child Neurol . 2008;50:112-116.
37.
Barkovich AJConcepts of myelin and myelination in neuroradiology . Am J Neuroradiol. 2000;21:1099-1109.
